Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. Show more

Location: 828 Winter Street, Waltham, MA, 02451, United States | Website: https://xiliotx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

37.51M

52 Wk Range

$0.61 - $1.70

Previous Close

$0.72

Open

$0.72

Volume

184,403

Day Range

$0.70 - $0.73

Enterprise Value

-76.69M

Cash

121.6M

Avg Qtr Burn

-3.332M

Insider Ownership

45.72%

Institutional Own.

25.46%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Vilastobart (XTX101)+ atezolizumab Details Metastatic microsatellite stable colorectal cancer (MSS CRC)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XTX301 Details Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XTX501 Details Solid tumor/s	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XTX202 (monotherapy) Details Renal cell carcinoma, Melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.